Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by GSK plc
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
August 01, 2024
From
GSK plc
Via
Business Wire
Tickers
GSK
GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season
July 11, 2024
From
GSK plc
Via
Business Wire
Tickers
GSK
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
June 07, 2024
From
GSK plc
Via
Business Wire
Tickers
GSK
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
June 03, 2024
From
GSK plc
Via
Business Wire
Tickers
GSK
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
June 02, 2024
From
GSK plc
Via
Business Wire
Tickers
GSK
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
March 16, 2024
From
GSK plc
Via
Business Wire
Tickers
GSK
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
March 07, 2024
From
GSK plc
Via
Business Wire
Tickers
GSK
GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk
February 06, 2024
From
GSK plc
Via
Business Wire
Tickers
GSK
GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity
December 12, 2023
From
GSK plc
Via
Business Wire
Tickers
GSK
GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative
November 13, 2023
From
GSK plc
Via
Business Wire
Tickers
GSK
New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease
October 25, 2023
From
GSK plc
Via
Business Wire
Tickers
GSK
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia
September 15, 2023
From
GSK plc
Via
Business Wire
Tickers
GSK
GSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations
September 05, 2023
From
GSK plc
Via
Business Wire
Tickers
GSK
GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies
August 17, 2023
From
GSK plc
Via
Business Wire
Tickers
GSK
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer
July 31, 2023
From
GSK plc
Via
Business Wire
Tickers
GSK
GSK is first to ship influenza vaccine doses for the 2023-24 flu season in US
July 13, 2023
From
GSK plc
Via
Business Wire
Tickers
GSK
US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend AREXVY for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making
June 21, 2023
From
GSK plc
Via
Business Wire
Tickers
GSK
GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons
June 21, 2023
From
GSK plc
Via
Business Wire
Tickers
GSK
GSK and Lifetime® Release Short Film Featuring Soleil Moon Frye and Melissa Joan Hart Urging Parents to “Ask2BSure” about Meningitis B
June 20, 2023
From
GSK plc
Via
Business Wire
Tickers
GSK
GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US
June 01, 2023
From
GSK plc
Via
Business Wire
Tickers
GSK
US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
May 03, 2023
From
GSK plc
Via
Business Wire
Tickers
GSK
GSK and Earvin “Magic” Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
March 14, 2023
From
GSK plc
Via
Business Wire
Tickers
GSK
New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients
December 11, 2022
From
GSK plc
Via
Business Wire
Tickers
GSK
ADDING MULTIMEDIA GSK and IQVIA launch Vaccine Track, a data trend platform to help improve adult vaccination in communities nationwide
August 08, 2022
From
GSK plc
Via
Business Wire
Tickers
GSK
GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis
July 27, 2022
From
GSK plc
Via
Business Wire
Tickers
GSK
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
July 11, 2022
From
GSK plc
Via
Business Wire
Tickers
GSK
GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
June 29, 2022
From
GSK plc
Via
Business Wire
Tickers
GSK
GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older
June 06, 2022
From
GSK plc
Via
Business Wire
Tickers
GSK
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.